Experiences with pharmacy benefit management programmes in the USA

International Journal of Risk and Safety in Medicine

Volumn 15, Issue 1-2, 2002, Pages 111-118

  Lipton, Helene L ^a   Duke, Kathryn S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COST UTILITY ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PROGRAM; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; PATIENT RIGHT; REVIEW;

EID: 0036971554     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. AB 974, Chapter 68, Statutes of 1998.
2. G. Borzo, Drug firms expand into patient care, American Medical News 39(24) (1996), 1,7,8.
3. General Accounting Office, Pharmacy Benefit Managers: FEHBP plans satisfied with savings and services, but retail pharmacies have concerns, GAO/HEHS-97-47, Washington, D.C., 1997.
4. M. Gibaldi, Vertical integration: the drug industry and prescription benefits managers, Pharmacotherapy 15 (1995), 265-271.
5. H.G. Grabowski and C.D. Mullins, Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions, Social Science & Medicine 45 (1997), 535-544.
6. IMS Health and Competitive Media Reporting release, 11/11/98.
7. L. Johannes, Some HMOs now put doctors on a budget for prescription drugs, Wall Street Journal (12 May 1997), A1.
8. D.H. Kreling, H.L. Lipton, T.C. Collins and K.C. Hertz, Assessment of the impact of pharmacy benefit managers, Final Report to the Health Care Financing Administration, National Technical Information Service, Springfield, VA, 1996, Pub. No. PB97-103683.
9. M. Lipsky, The opinions and experiences of family physicians regarding direct-to-consumer advertising, Journal of Family Practice 45(6) (1997), 495-499.
10. H.L. Lipton, L.H. Syed and M.R. Stebbins, Description and potential impact of pharmaceutical benefit management strategies in Medicare-risk HMOs: an exploratory study. Presented at Annual Meeting of the Gerontological Society of America, November 22, 1998, Philadelphia, Pennsylvania, USA.
11. R. Navarro, ed., Novartis Pharmacy Benefit Report: 1997 Trends and Forecasts, Totowa, New Jersey: Emron, Inc., 1997.
12. R. Navarro, ed., Novartis Pharmacy Benefit Report: 1998 Trends and Forecasts, Totowa, New Jersey: Emron, Inc., 1997.
13. Newark Star-Ledger, 1998, reported in 11/11 California Healthline.
14. R. O'Harrow Jr., Plans' access to pharmacy data raises privacy issue, Washington Post. (27 Sept. 1998), A1.
15. Prevention Magazine, reported in 11/11/98 California Healthline.
16. R.L. Rundle, CalPERS to pay 2.7% boost in HMO rates, Wall Street Journal (16 April 1997), A3.
17. SB 625, Chapter 69, Statutes of 1998.
18. K.A. Schulman, E. Rubenstein, D.R. Abernethy, D.M. Seils and D.P. Sulmasy, The effect of pharmaceutical benefits managers: is it being evaluated?, Annals of Internal Medicine 124 (1996), 906-913.
19. Time Magazine, reported in 11/11/98 California Healthline.
20. R.D. Waltermire, Direct-to-consumer advertising of Rx drugs can be harmful to your health, Drug Benefit Trends 10(10) (1998), 60-61.
21. J.B. White and R.L. Rundle, Big companies fight health-plan rates: employers demand HMOs and hospitals cut costs, Wall Street Journal (19 May 1998), A2.
22. R. Winslow, Health-care inflation revives in Minneapolis despite cost cutting, Wall Street Journal (19 May 1998), A1.